DT-diaphorase directed anti-tumor agents

US6156744A · kind A · utility

Assignees

• Cancer Research Campaign Tech (London) · US
• The Regents of the University of Technology Office of Technology Transfer · US
• UNIVERSITY OF SALFORD · GB

Inventors

• David Ross · Cary, US
• John Butler · Salford, GB
• Robert H. J. Hargreaves · Bury, GB
• David Siegel · Denver, US
• Howard D. Beall · Gainesville, US

Key dates

• Filing date: May 24, 1999
• Grant date: Dec 5, 2000
• Expiry date: May 24, 2019

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D203/08
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to a novel benzoquinone, 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone and its esters. The compounds can be used to treat tumors exhibiting elevated levels of the enzyme DT-diaphorase.